Metabolic reprogramming by mutant GNAS creates an actionable dependency in intraductal papillary mucinous neoplasms of the pancreas

Y Makino, KI Rajapakshe, BC Selvanesan, T Okumura… - Gut, 2025 - gut.bmj.com
Background Oncogenic 'hotspot'mutations of KRAS and GNAS are two major driver
alterations in intraductal papillary mucinous neoplasms (IPMNs), which are bona fide …

Glycogen synthase kinase 3β: a true foe in pancreatic cancer

OHM Elmadbouh, SJ Pandol… - International journal of …, 2022 - mdpi.com
Glycogen synthase kinase 3 beta (GSK-3β) is a serine/threonine protein kinase involved in
multiple normal and pathological cell functions, including cell signalling and metabolism …

[PDF][PDF] Mutant GNAS drives a pyloric metaplasia with tumor suppressive glycans in intraductal papillary mucinous neoplasia

VQH Trinh, KE Ankenbauer, SM Torbit, J Liu… - bioRxiv, 2024 - researchgate.net
ABSTRACT OBJECTIVE: Intraductal Papillary Mucinous Neoplasms (IPMNs) are cystic
lesions and bona fide precursors for pancreatic ductal adenocarcinoma (PDAC). Recently …

[HTML][HTML] Modern aspects of the management of pancreatic intraductal papillary mucinous neoplasms: a narrative review

ET Pavlidis, KG Sapalidis… - Romanian Journal of …, 2022 - ncbi.nlm.nih.gov
Intraductal papillary mucinous neoplasms (IPMNs) account for approximately 35% of all
cystic tumors in the pancreas and represent the largest subgroup. They are characterized by …

Exploiting Vulnerabilities in the Ras-Rac Signaling Pathway for the Selective Targeting of Pancreatic Cancer Cells

N Chaudhary - 2023 - digitalcommons.unmc.edu
Abstract Deregulation of the KRas (Kirsten rat sarcoma virus) GTPase is one of the early
hallmarks of Pancreatic Cancer (PC). The most common genetic alteration found in PC are …